Patients with increased activation of the HIF-1 signaling, PI3K-Akt signaling, or epithelial-mesenchymal transition (EMT) pathway and decreased interferon or IL6 immune responses might facilitate the tumor engraftment ability. The gene discussed is AKT1; the disease is neoplasm.